For glycemic control, metformin emerges as a particularly advantageous choice, not only for its established role in improving insulin sensitivity but also for its potential protective effects against gallstone formation, thereby providing comprehensive benefits in the management of both MetS and GSD risk. The gene discussed is INS; the disease is disorder of glycogen metabolism.